Genetic, molecular anomalies determine RCC therapy

Management of kidney cancer is advancing on several fronts, and this theme of continued progress is well illustrated by research being presented at the AUA annual meeting, said Robert C. Flanigan, MD.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.